All news from Hematology & Oncology

Potential Leukaemia Treatment with an Eye Drop Use

An active ingredient in eye drops that were being developed for the treatment of a form of eye disease has shown promise for treating an aggressive form of blood cancer. Scientists have found that this compound, which targets an essential cancer gene, could kill leukaemia cells without harming non-leukemic blood cells.  The results, published in Nature Communications reveal a potential new treatment approach for an aggressive blood cancer with a poor prognosis.

Survivors of Hodgkin Lymphoma Have High Risk of Tumors

New research refines existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. In addition, certain subgroups of patients have an especially high risk.

Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help refine guidelines for cancer screening in Hodgkin lymphoma survivors.

Treatment Intensification of Childhood Acute Lymphoblastic Leukemia

Refinement of risk-based treatment stratification by minimal residual disease (MRD) at different time points has improved outcomes of childhood acute lymphoblastic leukemia (ALL). In this prospective study, they evaluated effects of such stratification, including intensification of therapy based on response assessment at day-15 and MRD at day-29 of induction to test if treatment intensification would improve outcomes.